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Women who take folic acid periconceptionally reduce their risk of having a child with a neural tube defect (NTD)
by 150%. A variant form of methylenetetrahydrofolate reductase (MTHFR) (677CrT) is a known risk factor for
NTDs, but the prevalence of the risk genotype explains only a small portion of the protective effect of folic acid.
This has prompted the search for additional NTD-associated variants in folate-metabolism enzymes. We have
analyzed five potential single-nucleotide polymorphisms (SNPs) in the cytoplasmic, nicotinamide adenine dinucle-
otide phosphate–dependent, trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydro-
folate cyclohydrolase/formyltetrahydrofolate synthetase (MTHFD1) for an association with NTDs in the Irish
population. One SNP, R653Q, in this gene appears to be associated with NTD risk. We observed an excess of the
MTHFD1 “Q” allele in the mothers of children with NTD, compared with control individuals. This excess was
driven by the overrepresentation of QQ homozygotes in the mothers of children with NTD compared with control
individuals (odds ratio 1.52 [95% confidence interval 1.16–1.99], ). We conclude that genetic variationPp .003
in the MTHFD1 gene is associated with an increase in the genetically determined risk that a woman will bear a
child with NTD and that the gene may be associated with decreased embryo survival.
Neural tube defects (NTDs) are common congenitalmal-
formations that present mainly as anencephaly, encepha-
locele, and spina bifida. Genetic and environmental fac-
tors that produce alterations in folate metabolism are
likely to play a major role in the development of NTDs.
Use of folic acid to supplement periconceptional mater-
nal diet is known to prevent the majority of NTDs (MRC
Vitamin Study Research Group 1991; Czeizel andDudas
1992). In addition, decreased levels of folate in red blood
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cells and plasma (Kirke et al. 1993; Daly et al. 1995)
and elevated levels of homocysteine in plasma are as-
sociated with an increased risk of an NTD-affected preg-
nancy (Mills et al. 1995). A genetic component is evi-
denced by the increased risk to sibs of a child with NTD,
compared with the risk in the general population (l 1s
) and by the observation that NTD rates vary between10
different ethnic groups. For example, rates in people of
Celtic origin are relatively high, compared with levels in
African Americans (Elwood et al. 1992). The identifi-
cation and importance of these genetic factors has not
been completely elucidated. The genes that code for the
enzymes of the folate pathway are obvious candidates
to screen for variation associated with NTD risk. A poly-
morphism (A222V) dbSNP rs1801133 (historically re-
ferred to as “C677T”) in the enzyme 5,10-methylene-
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Figure 1 Role of MTHFD1 in DNA synthesis. The main role for MTHFD1 (shaded) is in providing 10-formyl THF and 5,10-methylene
THF for purine and pyrimidine synthesis. 10-Formyl THF can be synthesized directly from formate and THF, via the synthetase activity, or
from 5,10-methenyl THF, via the cyclohydrolase activity, which is channeled from 5,10-methylene THF via the dehydrogenase activity.MTHFD1
plays an indirect role in homocysteine metabolism by providing some of the 5,10-methylene THF pool, but the major source of this is SHMT.
The enzymes MTHFR and MS are directly involved in homocysteine metabolism.
tetrahydrofolate reductase (MTHFR [MIM 236250])
(Frosst et al. 1995) was subsequently associated with
lower folate status and increased risk of NTDs in some
populations (van der Put et al. 1995; Whitehead et al.
1995; Ou et al. 1996; de Franchis et al. 1998; Chris-
tensen et al. 1999). However, the association of the
MTHFR 677CrT polymorphism with NTDs remains
controversial, with several studies finding no association
(Papapetrou et al. 1996; Mornet et al. 1997; Speer et
al. 1997; Koch et al. 1998; Shaw et al. 1998; Weitkamp
et al. 1998; Boduroglu et al. 1999). Several additional
folate-related genes have also been examined in relation
to NTDs; however, no convincing associations have been
found, to date. Some of these genes include methionine
synthase, methionine synthase reductase, several folate
receptors, and cystathionine b-synthase (reviewed in Lu-
cock 2000; Melvin et al. 2000; Gelineau-van Waes and
Finnell 2001).
MTHFR plays an important role in folate metabolism
by catalyzing the reduction of 5,10-methylenetetrahy-
drofolate to 5-methyltetrahydrofolate, which acts as a
methyl group donor (Scott and Weir 1994) (fig. 1). The
MTHFR 677CrT polymorphism results in conversion
of an alanine to a valine, resulting in a “thermolabile”
variant of the enzyme (Kang et al. 1988). Individuals
who are homozygous for the thermolabile variant of
MTHFR (TT) have an increased risk of hyperhomocys-
teinemia and lower levels of folate in plasma and red
blood cells (Molloy et al. 1997). This polymorphism, in
combination with low folate status, was the first genetic
variant to show an association with NTDs in the Irish
population (Whitehead et al. 1995). The predominant
MTHFR-related genetic effect is observed in developing
embryos homozygous for the valine-containing allele
(TT). This genotype is estimated to account for 11.4%
of the population-attributable fraction (Shields et al.
1999). A meta-analysis of NTD risk associated with the
MTHFR 677TT case genotype results in a pooled odds
ratio (OR) of 1.8 (95% CI 1.4–2.2) (Botto and Yang
2000). Intervention trials and case-control studies in-
dicate that 150% of NTDs are preventable by pericon-
ceptional supplementation with folic acid (Scott et al.
1994). Therefore, the MTHFR 677CrT polymorphism
does not account for the majority of NTDs in the Irish
population, and other genetic and/or environmental fac-
tors may also be involved.
We have analyzed several potential polymorphisms
in another folate-dependent enzyme, methylene-
tetrahydrofolate dehydrogenase/methenyltetrahydro-
folate cyclohydrolase/formyltetrahydrofolate synthetase
(MTHFD1 [MIM 172460]), for an association with
NTDs.MTHFD1 is a trifunctional nicotinamide adenine
dinucleotide phosphate (NADP)–dependent cytoplasmic
enzyme (often referred to as “C1-THF synthase”), which
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catalyzes the conversion of tetrahydrofolate to the cor-
responding 10-formyl, 5,10-methenyl, and 5,10-meth-
ylene derivatives (fig. 1). 10-Formyltetrahydrofolate and
5,10-methylenetetrahydrofolate are the donor cofactors
for de novo purine and pyrimidine biosynthesis and,
thus, the biosynthesis of DNA. In eukaryotes the tri-
functional polypeptide exists as a homodimer with two
functionally distinct domains (Hum et al. 1988). The
NADP-dependent dehydrogenase and cyclohydrolase
activities share an overlapping active site on the NH2-
terminal domain (Barlowe et al. 1989). The COOH-
terminal domain possesses the formyltetrahydrofolate
synthetase activity and provides the source of 10-formyl-
tetrahydrofolate for purine biosynthesis. The synthetase
is also thought to play a noncatalytic role in purine bio-
synthesis by forming part of a purine-synthesizing mul-
tienzyme complex (Barlow and Appling 1990).
Our study population consisted of children with
NTDs, plus their parents (triads), whom we recruited
throughout Ireland from 1993 to the present with the
assistance of various branches of the Irish Association
for Spina Bifida and Hydrocephalus. The population
consisted of 319 complete NTD triads and a small
number of incomplete triads, in which DNA was not
available from all three family members (22 additional
children with NTD, 13 mothers, and 2 fathers). An
additional 83 mothers of children withNTDwere drawn
from a bank of previously collected samples (described
below and by Kirke et al. [1993]). Individuals from in-
complete triads and the bank sample were used in the
case-control comparisons only. Information about the
type of defect was available for 320 of the children with
NTD, and the group included 303 (95%) children with
spina bifida and 17 (5%) children with encephalocele.
Blood samples were collected from two populations in
addition to the NTD study population. Samples were
obtained between 1986 and 1990 from 56,049 pregnant
women attending the three main maternity hospitals in
the Dublin area. Details of this collection have been de-
scribed elsewhere (Kirke et al. 1993; Daly et al. 1995;
Mills et al. 1995). A set (83 individuals) of the 56,049
pregnant women was selected for genotyping and bio-
chemical analyses, because they subsequently gave birth
to an NTD-affected child. Information on the type of
defect was available for 80 of the NTD-affected preg-
nancies, which led to the birth of 40 (50%) children
with spina bifida, 33 (41%) children with anencephaly
or anencephaly plus spina bifida, and 7 (9%) children
with encephalocele or iniencephaly. This group of case
mothers was included with the case mothers from the
NTD study population in the final genotype compari-
sons. Control population I comprised a randomly se-
lected sample of these pregnant women (699 individuals)
who did not give birth to a child with NTD and who
had no previous history of an NTD-affected pregnancy.
Genotyping was performed on all of control population
I, and biochemical analyses were performed on a subset
(200 individuals) of this group. A further control pop-
ulation (control population II) consisted of 318 non-
pregnant women of childbearing age who were selected
from the students and staff of one of the Dublin ma-
ternity hospitals. Genotyping and biochemical analyses
were performed on samples from all members of this
control group. Details of control population II have been
described elsewhere (Molloy et al. 1997). Informed con-
sent and ethical approval were obtained for all samples
collected.
Several potential MTHFD1 SNPs were identified from
the public databases and the literature. A total of five
potential SNPs were chosen for analysis, because they
result in an amino acid change and therefore may alter
enzyme function. Of these, three were obtained from the
Single Nucleotide Polymorphism (dbSNP) Database and
were described as “tentative” SNPs (rs1950902, 401
GrA [R134K]; rs1803950, 2777 CrT [P926L]; and
rs1803951, 2380 GrT [G794C] [dbSNP]). The fourth
SNP was identified from the CGAP-GAI database (SNP
616138, 2282 CrT [T761M] [Cancer Genome Anat-
omy Project–Genetic Annotation Initiative]). Hol et al.
(1998) previously reported an additional SNP within the
coding region of MTHFD1, which also results in an
amino acid change (1958 GrA [R653Q]).
PCR assays for the MTHFD1 polymorphisms R134K,
P926L, G794C, and T761M were designed using the
genomic sequence of MTHFD1 (NT-025892 [Entrez]
and Primer Express (PE Applied Biosystems). To avoid
nonspecific amplification of the MTHFD-processed
pseudogene on the X chromosome (Italiano et al. 1991),
PCR primer sets were designed so that at least one
of the primers annealed to an intronic region of the
MTHFD1 sequence. Genotyping was performed using
either allele-specific–oligonucleotide (ASO) hybridiza-
tion or PCR-RFLP analysis. MTHFD1 SNPs P926L,
G794C, and T761M were not found to be variable in
230–300 Irish individuals. The MTHFD1 R134K is
polymorphic in the Irish population; it was PCR am-
plified using forward primer 5′-TTCCTTCTTATTTCC-
ATCACTT-3′ and reverse primer 5′-TTAGGCGTACAA-
GGAATGA-3′, and it was genotyped by ASO. The
MTHFD1 R653Q polymorphism was analyzed, essen-
tially, as described elsewhere (Hol et al. 1998), except
that the restriction enzyme MspI was used for the RFLP
analysis. Although the PCR primers for the MTHFD1
R653Q polymorphism were designed within the coding
region, amplification of the MTHFD pseudogene on the
X chromosome (Italiano et al. 1991) would be unlikely
because of two internal mismatches in the reverse primer
when aligned with the pseudogene sequence (data not
shown). In addition, the primers flank a 98-bp intron,
which allows detection of nonspecific pseudogene am-
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Table 1
Allele and Genotype Frequencies/Comparisons of the MTHFD1 Polymorphism R653Q in NTD Study Groups and
Control Individuals
FREQUENCIES AMONG MEMBERS
OF FAMILIES WITH NTD
FREQUENCIES AMONG
CONTROL GROUPS
Fathers
(n p 310)
Children
(n p 336)
Mothers
(n p 410)
Ia
(n p 691)
IIb
(n p 306)
I and II
(n p 997)
Genotype:
RR 106 (.34) 101 (.30) 108 (.26) 185 (.27) 98 (.32) 283 (.28)
RQ 144 (.46) 178 (.53) 195 (.48) 377 (.55) 149 (.49) 526 (.53)
QQ 60 (.19) 57 (.17) 107 (.26) 129 (.19) 59 (.19) 188 (.19)
Allele:
R .57 .57 .50 .54 .56 .55
Q .43 .43 .50 .46 .44 .45
Comparisons of family members and
control groups (QQ vs. RQ/RR):
OR OR (LL)c OR (UL)d Pe
Mothers/control groups 1.52 1.16 1.99 .003
Children/control groups .88 .63 1.22 .439
Fathers/control groups 1.03 .75 1.43 .845
NOTE.—Data in parentheses are genotype frequencies. Because of rounding, some columns of genotype frequencies may
not sum to 1.
a Control group I consists of pregnant women, as described in the text.
b Control group II consists of nonpregnant women of childbearing age, as described in the text.
c LL p lower limit of 95% CI.
d UL p upper limit of 95% CI.
e Assessed with use of x2 analysis.
plification on the basis of size difference (i.e., 330 bp
for the functional MTHFD1 gene and 232 bp for the
pseudogene). Nonspecific amplification of the pseudo-
gene was never observed in our sample set. Moreover,
the PCR products of several randomly selected samples
were sequenced, and all contained the expected 98-bp
intron. A final quality control check included repeat
MTHFD1 R653Q genotyping of ∼10% of our samples
with an independent PCR assay using a different set of
intronic primers and the restriction enzyme AlwI.
The SNPs MTHFD1 R653Q and R134K were poly-
morphic in our sample set, and we were able to assign
unambiguous R653Q genotypes to 98% (2,053/2,094)
of our samples and to assign R134K genotypes to 97.5%
(2,042/2,094). The rate of genotype failure did not differ
between the groups. The allele/genotype frequencies and
comparisons for each group are summarized in tables 1
and 2. There was no evidence of linkage disequilibrium
between the two SNPs (data not shown). Allele and ge-
notype frequencies did not differ significantly between
the two control groups. These groups were pooled for
subsequent comparisons. Analysis of the R653Q allele
frequencies show a significant excess of theQ-containing
allele in the mothers of children with NTD, compared
with control individuals (OR 1.20 [95% CI 1.02–1.42],
). The increased frequency of the “Q” allele isPp .025
due to the increased frequency of maternal QQ homo-
zygotes, because comparisons based on genotype (QQ
vs. RQ/RR) show a highly significant difference in the
frequency of QQ homozygotes in case mothers, com-
pared with controls (OR 1.52 [95% CI 1.16–1.99],
) (table 1). Similar results are obtained whenPp .003
case mothers are compared with control populations
separately (control population I OR 1.54 [95% CI
1.15–2.06, ; control population II OR 1.48Pp .004
[95% CI 1.03–2.12], ). Moreover, when typePp .033
of NTD is taken into account, maternal QQ homozy-
gosity remains a risk factor in each NTD subgroup, com-
pared with controls (spina bifida [ ] OR 1.43np 337
[95% CI 1.07–1.92], ; anencephaly or anen-Pp .017
cephaly plus spina bifida [ ] OR 2.46 [95% CInp 33
1.19–5.09], ; encephalocele [ ] OR 3.01Pp .015 np 17
[95% CI 1.13–8.02], ). Despite small numbers,Pp .027
the maternal effects are strong enough to reach statis-
tical significance in each subgroup. The frequency of
MTHFD1 R653Q heterozygotes did not differ between
the study and control groups. Therefore, heterozygotes
and RR homozygotes were combined to calculate the
population-attributable risk (the proportion of cases in
the total population that can be attributed to the risk
fact) associated with homozygosity for the Q allele. Un-
der the assumption that it is an independent risk factor,
8.9% (95%CI 2.8%–14.6%) of NTDs can be attributed
to this allele. Analysis of the R134K data shows some
enrichment of the “K” allele in children with NTD, com-
pared with controls (KK/RK vs. RR), but this is not
statistically significant (OR 1.25 [95% CI 0.96–1.62],
) (table 2).Pp .098
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Table 2
Allele and Genotype Frequencies/Comparisons of the MTHFD1 Polymorphism R134K in NTD Study Groups and
Control Individuals
FREQUENCIES AMONG MEMBERS
OF FAMILIES WITH NTD
FREQUENCIES AMONG
CONTROL GROUPS
Fathers
(n p 314)
Children
(n p 335)
Mothers
(n p 404)
I
(n p 676)
II
(n p 313)
I and II
(n p 989)
Genotype:
RR 205 (.65)D 216 (.64) 267 (.66) 474 (.70) 212 (.68) 686 (.69)
RK 101 (.32) 112 (.33) 122 (.30) 187 (.28) 90 (.29) 277 (.28)
KK 8 (.03) 7 (.02) 15 (.04) 15 (.02) 11 (.04) 26 (.03)
Allele:
R .81 .81 .81 .84 .82 .83
K .19 .19 .19 .16 .18 .17
Comparisons of family members and
control groups (KK/RK vs. RR):
OR OR (LL) OR (UL) P
Mothers/control groups 1.16 .91 1.49 .233
Children/control groups 1.25 .96 1.62 .098
Fathers/control groups 1.20 .92 1.58 .176
NOTE.—Because of rounding, some columns of genotype frequencies may not sum to 1. Control groups and abbreviations
are as defined in table 1.
The transmission/disequilibrium test (TDT) (Spielman
et al. 1993) was performed on informative MTHFD1
R653Q and R134K heterozygotes from our NTD triad
sample set. Comparisons of allele transmission from in-
formative heterozygous parents to children with NTD
was performed by use of the McNemar test. Allele trans-
mission from informative R653Q heterozygotes (np
) (triads in which both parents and cases are het-215
erozygous or homozygous are not informative) showed
favorable transmission of the wild-type “R” allele (R:
58%, ; Q: 41%, ; , McNemarnp 126 np 89 Pp .014
x2 6.03). In addition to the standard TDT, the five con-
ditional models described by Schaid (1999) were also
fitted to the triad data. The best-fitting model was the
recessive model, which includes only the relative risk for
the QQ allele in the cases. This was estimated to be 0.61
(SE 0.12) ( , ). Transmission of the R2x p 6.20 Pp .013
allele was even more apparent when the TDT was per-
formed on heterozygotes ( ) only where a QQnp 125
homozygote case is possible (i.e., exclusion of triads in
which one parent is RR [R: 63%, ; Q: 37%,np 79
; , McNemar x2 8.19]). TDT analysisnp 46 Pp .004
of informative R134K heterozygotes ( ) showednp 150
approximately equal transmission of each allele (R:
49%, ; K: 51%, ; , McNemarnp 74 np 76 Pp .935
x2 0.007). However, when the TDT was performed only
on heterozygotes ( ) where a KK homozygote casenp 33
is possible, again preferential transmission of the wild-
type R allele is observed (R: 83%, ; K: 17%,np 24
; , McNemar x2 5.94).np 9 Pp .015
We analyzed our R653Q triad data further by apply-
ing log-linear models, which provide a powerful test of
allele transmission, assuming Hardy-Weinberg equilib-
rium (Weinberg et al. 1998) (table 3). An important
feature of the log-linear model is that it can include both
case and maternal effects, both individually and jointly
in the same model. Models for both recessive (Case QQ
and Mother QQ effects in table 3) and dominant (Case
QQ or RQ and Mother QQ or RQ) effects were sepa-
rately fitted. Like the results in table 1, this analysis
shows an increased QQ maternal risk (relative risk 1.42
[SE 0.24], ). Moreover, it demonstrates a sig-Pp .034
nificantly lower number of QQ cases than expected (rel-
ative risk 0.62 [SE 0.11], ). The relative risk isPp .007
very similar to the estimate obtained using the recessive
model of Schaid, which does not permit the inclusion of
maternal effects. A joint effect of the maternal and case
genotypes is also evidenced ( ) (table 3). Con-Pp .003
sistent with the results shown in table 1, this analysis,
table 3, shows an increased QQ maternal risk (relative
risk 1.42, ). Moreover, it also demonstrates aPp .034
significantly lower number of QQ cases than expected
(relative risk 0.62, ). We also performed anPp .007
additional log-linear–model analysis by including the
controls to provide a more accurate estimate of Hardy-
Weinberg equilibrium (table 3). This analysis gives sim-
ilar results. The log-linear models could not be applied
to the R134K data because of limited genotype numbers.
The MTHFD1 R653Q and R134K polymorphisms
may result in disturbance of the folate-mediated homo-
cysteine pathway and therefore may alter folate or hom-
ocysteine levels. Assays that measure levels of folate in
plasma and red blood cell, as well as homocysteine levels
in plasma, had been performed previously on a subset
of our study and control populations (Kirke et al. 1993;
Daly et al. 1995; Mills et al. 1995; Molloy et al. 1997,
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Table 3
MTHFD1 R653Q Log-Linear Models of Case and Maternal Effects within Parent-Case Triads
Alone and Combined with Control Individuals
Genotype
Case
G2
Relative
Risk P
Case and Control
G2
Relative
Risk P
No effect 17.37 21.77
Case QQ 10.09 .62 .0070 16.98 .70 .029
Case QQ or RQ 17.14 .93 .63 21.74 .98 .85
Mother QQ 12.89 1.42 .034 17.47 1.35 .038
Mother QQ or RQ 16.14 1.19 .27 20.37 1.18 .24
Combined QQ: 5.60 .0027 10.13 .0030
Case QQ .62 .0070 .64 .0067
Mother QQ 1.42 .034 1.48 .0088
Combined QQ/RQ: 15.91 .48 19.28 .28
Case QQ or RQ .93 .63 .93 .30
Mother QQ or RQ 1.19 .27 1.20 .12
NOTE.—G2 is the likelihood ratio goodness-of-fit statistic for the model containing the par-
ticular effect(s). Differences of these values are x2 statistics for the effect(s). G2 p 0.21 (like-
lihood-ratio x2 statistic with 1 df) for equality of Hardy-Weinberg equilibrium (frequency of
Q allele) between cases and controls. ; .ˆ ˆp p 0.461 p p 0.452cases controls
1998). Results of each assay were grouped on the basis
of each genotype and were compared. No biochemical
differences were observed between genotypes among
control nonpregnant women, case pregnant mothers,
and control pregnant mothers (data not shown).
In summary, our analysis of five SNPs in theMTHFD1
gene showed that both MTHFD1 R653Q and R134K
SNPs are polymorphic in the Irish population. The
MTHFD1 R653Q allele frequencies reported here are
similar to those previously found in the Dutch (Hol et
al. 1998) and Turkish (Akar and Akar 1999) popula-
tions (i.e., ∼0.55 for the R allele and 0.45 for the Q
allele). As in the Dutch study (Hol et al. 1998), we did
not observe a significant difference in allele or genotype
frequencies between the case and control groups. How-
ever, our study also included the parents of children with
NTD, and a comparison between groups shows an ov-
errepresentation of QQ homozygotes among the case
mothers, compared with controls. Our results predict
that mothers with the MTHFD1 “QQ” genotype have
an increased risk (∼1.5- to 2.0-fold) of having an NTD-
affected pregnancy. The absence of any difference be-
tween children with NTD and controls (table 1) suggests
that this is a maternal effect only, and we would there-
fore expect approximately equal transmission of either
allele, by the TDT. However, we observe preferential
transmission of the wild-type R allele to children with
NTD ( ), and this transmission is enhanced evenPp .014
further when the TDT is performed only when a QQ
homozygote case is possible ( ). In addition toPp .004
these data, the log-linear approach shows similar results
(table 3), in that QQ homozygosity is overrepresented
in mothers of children with NTD and underrepresented
in children with NTD. This is in contrast to what is
expected for a maternal risk factor (i.e., approximately
equal transmission of either allele, by the TDT, and a
possible enrichment of the risk allele in the cases because
of their mothers’ genotype [Labuda et al. 2002]). This
suggests that the QQ genotype may be having a different
effect in the embryo. One possibility is that the QQ
genotype in the embryo results in decreased viability. The
QQ genotype may produce more severely affected NTD
embryos that do not survive to birth or may exert a
viability effect unrelated to NTDs. This effect may be
influenced by the maternal genotype as the log-linear
analysis does indicate a combined effect of the mother
and case genotypes (table 3). A second possibility is that,
in QQ mothers, the QQ genotype in the embryo may
be protective against NTDs, and therefore we observe
fewer QQ homozygote NTD cases than were expected.
Thus, there appears to be both a clear maternal NTD
risk with the QQ genotype and a suggestion that QQ
homozygosity in the embryo is associated with decreased
viability or is protective against NTDs. The MTHFD1
R134K polymorphism has an allele frequency of 0.17
and therefore is less abundant than the R653Q poly-
morphism. This SNP may have a small risk for NTD
cases, but a sample size larger than that described here
will be required to establish the significance of this
finding.
The MTHFD1 R653Q polymorphism lies within
the 10-formyltetrahydrofolate synthetase domain of
MTHFD1. This residue is also an arginine in the
rat, mouse, and some fungal orthologs of MTHFD1.
MTHFD1 in other species (including numerous prokar-
yotes, insects, plants, and fungi) contain a nearly equiv-
alent lysine at this residue. This cross-kingdom conser-
vation suggests that the replacement of this amino acid
with a glutamine may have direct functional conse-
quences. Alternatively, this SNP may be in linkage dis-
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equilibrium with another, as yet undescribed, variant
that alters function. The MTHFD1 R134K lies within
the dehydrogenase/cyclohydrolase domain of the en-
zyme, but this arginine residue is not conserved in other
species and is a lysine in the rat and a glutamic acid in
yeast. Therefore, the evidence for an association with
NTDs is more convincing for the R653Q variant than
for the R134K variant.
The MTHFD1 R653Q data show a clear excess of
QQ homozygotes in mothers of children with NTD,
compared with controls, and suggest that this variant
(or a variant in linkage disequilibrium) plays a role in
abnormal neural tube closure. Analysis by NTD type
shows that the maternal QQ genotype remains a risk
factor in spina bifida, anencephaly or anencephaly plus
spina bifida, and encephalocele groups. We did not ob-
serve an obvious correlation between MTHFD1 R653Q
genotype and levels of folate in plasma or red blood cells
or between genotype and levels of homocysteine among
mothers of patients with NTD or control individuals.
However, this is not unexpected, because MTHFD1 is
an important provider of carbon-1 units for de novo
purine and pyrimidine synthesis (West et al. 1996). Al-
though it indirectly provides carbon-1 units via 5,10-
methylenetetrahydrofolate for methylation reactions, its
role in this is less important than that of cytoplasmic
serine hydroxymethyltransferase (which also provides
5,10-methylenetetrahydrofolate) (fig. 1). Consequently,
its function in supplying methyl groups for methylation
reactions may be unimportant, and thus an alteration
of its activity caused by a polymorphic variant, such as
MTHFD1 R653Q, might not be expected to result in
elevation of plasma homocysteine levels. Moreover, the
synthetase domain is also thought to play a noncatalytic
role in purine synthesis (Barlowe and Appling 1990;
West et al. 1996), and thus a polymorphism that has no
effect on its enzyme activity may have an effect on DNA
synthesis because of an alteration of a necessary mul-
tiprotein complex. Thus, the MTHFD1 enzyme may
play a key role in cell division and therefore may have
an important influence on the maternal environment. At
the time of neural tube closure (days 21–27), the embryo
is entirely dependent upon maternally derived cells that
protect and nurture its development. The synthetase ac-
tivity provides the source of 10-formyltetrahydrofolate,
which is essential for rapidly dividing cells, which require
2 mol of 10-formyltetrahydrofolate per mole of purine
ring. MTHFD1 QQ homozygote mothers may have less
efficient purine or pyrimidine synthesis, which is critical
during early development. The preferential transmission
of the wild-type R allele and the less-than-expected fre-
quency of QQ cases also suggests that this variant (or
a variant in linkage disequilibrium with R653Q and
R134K) may be linked to embryo loss or may be pro-
tective against NTDs, but further analysis is required.
The identification of the maternal MTHFD1 R653Q
genotype as a genetic risk factor for NTDs emphasizes
both the importance of folate-dependent pathways and
the maternal influence on neural tube development.
MTHFD1 is only the second folate-related gene to be
identified as a risk factor for NTDs, and identification
of the gene helps to explain the protective effect of folic
acid against NTDs. Further analyses will aid in eluci-
dating the exact mechanism by which genetic variants,
such as MTHFR 677CrT and MTHFD1 R653Q, affect
neural tube closure.
Acknowledgments
This work was supported by the National Institute of Child
Health and Human Development, National Institutes ofHealth,
and the Health Research Board of Ireland (in particular by their
provision of the ABI 377 automated DNA sequencer).We thank
the Irish Association for Spina Bifida and Hydrocephalus for
their assistance with subject recruitment. We wish to thank He-
len Burke, Miriam Lynch, Sharon Murray, Deborah Watson,
and Marie Sutton for subject recruitment and data collection.
We thank the three Dublin maternity hospitals (National Ma-
ternity Hospital Holles Street, the Coombe Womens’ Hospital,
and the Rotunda Hospital) and, particularly, Dr. Sean Daly,
Master of the Coombe Womens’ Hospital, for control recruit-
ment. We thank Mary Cuneen, Regina Dempsey, Tracey Clax-
ton, and Rebecca Seltzer for their technical assistance.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Cancer Genome Anatomy Project–Genetic Annotation Initia-
tive (CGAP-GAI), http://cgap.nci.nih.gov/ (for MTHFD1
2282 CrT [SNP 616138])
Entrez, http://www.ncbi.nlm.nih.gov/Entrez/ (for MTHFD1
sequence [NT-025892])
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for MTHFR [MIM 236250] and
MTHFD1 [MIM 172460])
Single Nucleotide Polymorphism Database, http://www.ncbi
.nlm.nih.gov/SNP/ (for MTHFD1 401 GrA [rs1950902],
MTHFD1 2777 CrT [rs1803950], MTHFD1 2380 GrT
[rs1803951], and MTHFR 677CrT [rs1801133])
References
Akar N, Akar E (1999) Methylenetetrahydrofolate-dehydro-
genase 1958 GrA (R653Q) polymorphism in Turkish pa-
tients with venous thromboembolism. Acta Haematol 102:
199–200
Barlowe CK, Appling DR (1990) Molecular genetic analysis
of Saccharomyces cerevisiae C1-tetrahydrofolate synthase
mutants reveals a noncatalytic function of the ADE3 gene
product and an additional folate-dependent enzyme. Mol
Cell Biol 10:5679–5687
1214 Am. J. Hum. Genet. 71:1207–1215, 2002
Barlowe CK, Williams ME, Rabinowitz JC, Appling DR
(1989) Site-directed mutagenesis of yeast C1-tetrahydrofol-
ate synthase: analysis of an overlapping active site in a mul-
tifunctional enzyme. Biochemistry 28:2099–2106
Boduroglu K, Alikasifoglu M, Anar B, Tuncbilek E (1999)
Association of the 677CrT mutation on the methylene-
tetrahydrofolate reductase gene in Turkish patients with neu-
ral tube defects. J Child Neurol 14:159–161
Botto LD, Yang Q (2000) 5,10-Methyleneterahydrofolate re-
ductase gene variants and congenital anomalies: a HuGE
review. Am J Epidemiol 151:862–877
Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N,
Platt R, Gilfix BM, Rosenblatt DS, Gravel RA, Forbes P,
Rozen R (1999) Genetic polymorphisms in methylene-
tetrahydrofolate reductase and methionine synthase, folate
levels in red blood cells, and risk of neural tube defects. Am
J Med Genet 84:151–157
Czeizel AE, Dudas I (1992) Prevention of the first occurrence
of neural tube defects by periconceptual vitamin supple-
mentation. N Engl J Med 327:1832–1835
Daly LE, Kirke PN, Molloy AM, Weir DG, Scott JM (1995)
Folate levels and neural tube defects: implications for pre-
vention. JAMA 274:1698–1702
de Franchis R, Buoninconti A,Mandato C, Pepe A, Speerandeo
MP, Del Gado R, Capra V, Salvaggio E, Andria G, Mas-
troiacovo P (1998) The C677T mutation of the 5,10-meth-
ylenetetrahydrofolate reductase gene is a moderate risk fac-
tor for spina bifida in Italy. J Med Genet 35:1009–1013
Elwood JM, Little J, Elwood JH (1992) Epidemiology and con-
trol of neural tube defects. Oxford University Press, Oxford
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mat-
thews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van
den Heuvel LP, Rozen R (1995) A candidate genetic risk
factor for vascular disease: a common mutation in methy-
lenetetrahydrofolate reductase. Nat Genet 10:111–113
Gelineau-Van Waes J, Finnell RH (2001) Genetics of neural
tube defects. Semin Pediatr Neurol 8:160–164
Hol FA, van der Put NMJ, Geurds MPA, Heil SG, Trijbels
FJM, Hamel BCJ, Mariman ECM, Blom HJ (1998) Mo-
lecular genetic analysis of the gene encoding the trifunc-
tional enzyme MTHFD (methylenetetrahydrofolate-de-
hydrogenase, methenyltetrahydrofolate-cyclohydrolase,
formyltetrahydrofolate synthetase) in patients with neu-
ral tube defects. Clin Genet 53:119–125
Hum DW, Bell AW, Rozen R, MacKenzie RE (1988) Primary
structure of a human trifunctional enzyme: isolation of a
cDNA encoding methylenetetrahydrofolate-dehydrogenase,
methenyltetrahydrofolate-cyclohydrolase, formyltetrahydro-
folate synthetase. J Biol Chem 263:15946–15950
Italiano C, John SW, Hum DW, MacKenzie RE, Rozen R
(1991) A pseudogene on the X chromosome for the human
trifunctional enzyme MTHFD (methylenetetrahydrofolate-
dehydrogenase, methenyltetrahydrofolate cyclohydrolase,
formyltetrahydrofolate synthetase). Genomics 10:1073–
1074
Kang S-S, Wong PWK, Zhou J, Sora J, Lessick M, Ruggie N,
Grcevich G (1988) Thermolabile methylenetetrahydrofolate
reductase in patients with coronary artery disease. Metab-
olism 37:611–613
Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott
JM (1993) Maternal plasma folate and vitamin B12 are in-
dependent risk factors for neural tube defects. Q J Med 86:
703–708
KochMC, Stegmann K, Ziegler A, Schroter B, Ermert A (1998)
Evaluation of the MTHFR C677T allele and the MTHFR
gene locus in a German spina bifida population. Eur J Pe-
diatr 157:487–492
Labuda D, KrajinovicM, Sabbagh A, Infante-Rivard C, Sinnett
D (2002) Parental genotypes in the risk of a complex disease.
Am J Hum Genet 71:193–197
Lucock M (2000) Folic acid: nutritional biochemistry, molec-
ular biology, and role in disease processes. Mol GenetMetab
71:121–138
Melvin EC, George TM, Worley G, Franklin A, Mackey J,
Viles K, Shah N, Drake CR, Enterline DS, McLone D, Nye
J, Oakes WJ, McLaughlin C, Walker ML, Peterson P, Brei
T, Buran C, Aben J, Ohm B, Bermans I, QumsiyehM, Vance
J, Pericak-Vance MA, Speer MC (2000) Genetic studies in
neural tube defects—NTD Collaborative Group. Pediatr
Neurosurg 32:1–9
Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir
DG, Scott JM (1995) Homocysteine metabolism in preg-
nancies complicated by neural tube defects. Lancet 345:149–
151
Molloy AM, Daly S, Mills JL, Kirke PN,Whitehead AS, Rams-
bottom D, Conley MR, Weir DG, Scott JM (1997) Ther-
molabile variant of 5,10-methylenetetrahydrofolate reduc-
tase associated with low red-cell folates: implications for
folate intake recommendations. Lancet 349:1591–1593
Molloy AM, Mills JL, Kirke PN, Ramsbottom D, McPartlin
JM, Burke H, Conley M, Whitehead AS, Weir DG, Scott
JM (1998) Low blood folates in NTD pregnancies are only
partly explained by thermolabile 5,10-methylenetetrahydro-
folate reductase: low folate status alone may be the critical
factor. Am J Med Genet 78:155–159
Mornet E, Muller F, Lenvoise-Furet A, Delezoide A-L, Col
J-Y, Simon-Bouy B, Serre J-L (1997) Screening of the C677T
mutation on the methylenetetrahydrofolate reductase gene
in French patients with neural tube defects. HumGenet 100:
512–514
MRC Vitamin Study Research Group (1991) Prevention of
neural tube defects: results of the Medical Research Council
vitamin study. Lancet 338:131–137
Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP,
Khoury MJ, Rozen R, Oakley GP Jr, Adams MJ Jr (1996)
5,10-Methylenetetrahydrofolate reductase genetic polymor-
phism as a risk factor for neural tube defects. Am J Med
Genet 63:610–614
Papapetrou C, Linch SA, Burn J, Edwards YH (1996) Meth-
ylenetetrahydrofolate reductase and neural tube defects.
Lancet 348:58
Schaid DJ (1999) Likelihoods and TDT for the case-parent
design. Genet Epidemiol 16:250–260
Scott JM, Weir DG (1994) Folate/vitamin B12 inter-relation-
ships. Essays Biochem 28:63–72
Scott JM, Weir DG, Molloy A, McPartlin J, Daly L, Kirke P
(1994) Folic acid metabolism andmechanisms of neural tube
defects. In: Bock G, Marsh J (eds) Ciba Foundation Sym-
posium 181: Neural tube defects. JohnWiley& Sons, Chich-
ester, United Kingdom, pp 180–191
Reports 1215
Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ
(1998) Maternal vitamin use, genetic variation of infant
methylenetetrahydrofolate reductase, and risk for spina bi-
fida. Am J Epidemiol 148:30–37
Shields DC, Kirke PN, Mills JL, Ramsbottom D, Molloy AM,
Burke H, Weir DG, Scott JM, Whitehead AS (1999) The
“thermolabile” variant of methylenetetrahydrofolate reduc-
tase and neural tube defects: an evaluation of genetic risk
and the relative importance of the genotypes of the embryo
and the mother. Am J Hum Genet 64:1045–1055
Speer MC, Worley G, Mackey JF, Melvin E, OakesWJ, George
TM, Group NC (1997) The thermolabile variant of meth-
ylenetetrahydrofolate reductase (MTHFR) is not a major
risk factor for neural tube defect in American Caucasians.
Neurogenetics 1:149–150
Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission
test for linkage disequilibrium: the insulin gene region and
insulin-dependent diabetes mellitus (IDDM). Am J HumGe-
net 52:506–511
van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels
FJM, Eskes TKAB, van den Heuvel LP, Mariman ECM, den
Heyer M, Rozen R, Blom HJ (1995) Mutated methylene-
tetrahydrofolate reductase as a risk factor for spina bifida.
Lancet 346:1070–1071
Weinberg CR,Wilcox AJ, Lie RT (1998) A log-linear approach
to case-parent–triad data: assessing effects of disease genes
that act either directly or through maternal effects and that
may be subject to parent imprinting. Am J Hum Genet 62:
969–978
Weitkamp LR, Tackels DC, Hunter AGW, Holmes LB,
Schwartz CE (1998) Heterozygote advantage of theMTHFR
gene in patients with neural-tube defect and their relatives.
Lancet 351:1554–1555
West MG, Horne DW, Appling DR (1996) Metabolic role of
cytoplasmic isozymes of 5,10-methylenetetrahydrofolate de-
hydrogenase in Saccharomyces cerevisiae. Biochemistry 35:
3122–3132
Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H,
Molloy AM, Weir DG, Shields DC, Scott JM (1995) A ge-
netic defect in 5,10-methylenetetrahydrofolate reductase in
neural tube defects. Q J Med 88:763–766
